Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
Ahrén B, Galstyan G, Gautier JF, Giorgino F, Gomez-Peralta F, Krebs M, Nikonova E, Stager W, Vargas-Uricoechea H. Ahrén B, et al. Among authors: galstyan g. Diabetes Ther. 2016 Sep;7(3):583-90. doi: 10.1007/s13300-016-0179-6. Epub 2016 Jun 18. Diabetes Ther. 2016. PMID: 27319011 Free PMC article.
Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa.
Giorgino F, Bhana S, Czupryniak L, Dagdelen S, Galstyan GR, Janež A, Lalić N, Nouri N, Rahelić D, Stoian AP, Raz I. Giorgino F, et al. Diabetes Res Clin Pract. 2021 Feb;172:108617. doi: 10.1016/j.diabres.2020.108617. Epub 2020 Dec 10. Diabetes Res Clin Pract. 2021. PMID: 33310175 Free PMC article. Review.
Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
Davies MJ, Russell-Jones D, Barber TM, Lavalle-González FJ, Galstyan GR, Zhu D, Baxter M, Dessapt-Baradez C, McCrimmon RJ. Davies MJ, et al. Diabetes Obes Metab. 2019 Aug;21(8):1967-1972. doi: 10.1111/dom.13791. Epub 2019 Jun 18. Diabetes Obes Metab. 2019. PMID: 31124299 Free PMC article. Clinical Trial.
Lifestyle modification program, LIFE is LIGHT, in patients with type 2 diabetes mellitus and obesity: Results from a 48-week, multicenter, non-randomized, parallel-group, open-label study.
Galstyan GR, Valeeva FV, Motkova SI, Surkova EV, Savelyeva LV, Rudina LM, Ramanathan K, Sokareva E, Bondareva K, Shestakova MV. Galstyan GR, et al. Obes Sci Pract. 2021 Apr 9;7(4):368-378. doi: 10.1002/osp4.502. eCollection 2021 Aug. Obes Sci Pract. 2021. PMID: 34401196 Free PMC article.
79 results